Stock Updates

Is this Large Market Cap Stock target price reasonable for Neurocrine Biosciences Inc. (NASDAQ:NBIX)?

The company in question is, Neurocrine Biosciences Inc. (NASDAQ:NBIX) currently with a stock price of 43.03 (-2.55% today). The market cap for Neurocrine Biosciences Inc. is 3879.01, and is in the sector Healthcare, and Drugs – Generic industry. The target price for Neurocrine Biosciences Inc. is 70.5. Currently Neurocrine Biosciences Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Neurocrine Biosciences Inc. is 750.58 and so far today it is 236463.

Performance in the last year for Neurocrine Biosciences Inc. has been -1.01%. For EPS growth, Neurocrine Biosciences Inc. has seen a growth of -29.60%, and is looking to grow in the next year to -1.60%. More long term stats show that EPS growth has been -47.50% over the last five years and could be -9.18% for the next five years. Neurocrine Biosciences Inc. has seen sales growth quarter over quarter at *TBA, with EPS growth quarter over quarter at -65.60%. The 20-day simple moving average is -13.81%, with the 200-day simple moving average coming to -5.34%.

Since the IPO date for Neurocrine Biosciences Inc. on the 5/23/1996, Neurocrine Biosciences Inc. has seen performance year to date to be -21.94%. With Neurocrine Biosciences Inc. trading at 43.03, the dividend yield is *TBA, and the EPS is -1.43.

So could Neurocrine Biosciences Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 258.6 and the P/B is at 10.04. The P/cash is 10.01, with P/free cash flow at *TBA.

Neurocrine Biosciences Inc. ability to deal with debt shows that the current ratio is 14.6, and the quick ratio is 14.6. This is with long term debt/equity at 0, and total debt/equity at 0.

In terms of margins, Neurocrine Biosciences Inc. has a gross margin of *TBA, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Neurocrine Biosciences Inc. is *TBA. Return on assets come to -26.60% with return on investment coming to -22.20%.

Insider ownership for Neurocrine Biosciences Inc., is at 0.50% and institutional ownership comes to 98.10%. Outstanding shares are at 87.84. While shares float is 85.72. The float short is currently 5.86%, and short ratio is 6.69.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment